Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. [electronic resource]
Producer: 20121227Description: 192-9 p. digitalISSN:- 1546-9549
- Carbolines -- therapeutic use
- Cardiomyopathy, Dilated -- drug therapy
- Cyclic AMP -- metabolism
- Cyclic GMP -- metabolism
- Cyclic GMP-Dependent Protein Kinases -- drug effects
- Cyclic Nucleotide Phosphodiesterases, Type 5 -- metabolism
- Fibrosis
- Heart -- drug effects
- Heart Failure -- drug therapy
- Humans
- Hypertrophy
- Myocardium -- metabolism
- Phosphodiesterase 5 Inhibitors -- therapeutic use
- Phosphoric Diester Hydrolases -- drug effects
- Piperazines -- therapeutic use
- Purines -- therapeutic use
- Sildenafil Citrate
- Sulfones -- therapeutic use
- TRPC Cation Channels -- metabolism
- Tadalafil
- Transforming Growth Factor beta -- metabolism
- Ventricular Remodeling -- physiology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review
There are no comments on this title.
Log in to your account to post a comment.